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 William Scott  Argraves ,  PhD ;  Rema A.  Oliver ,  PhD ;  Brian G.  Oliver ,  PhD ; Judith L.  Black ,  MBBS ,  PhD ; 
and  Janette K.  Burgess ,  PhD 
 BACKGROUND:  The underlying mechanisms of idiopathic pulmonary fibrosis (IPF) are 
unknown. Th is progressive disease has high mortality rates, and current models for prediction 
of mortality have limited value in identifying which patients will progress. We previously 
showed that the glycoprotein fi bulin-1 is involved in enhanced proliferation and wound repair 
by mesenchymal cells and, thus, may contribute to lung fi brosis in IPF. 
 METHODS:  Serum, lung tissue, and lung function values were obtained from four independent 
locations (Sydney, NSW, and Perth, WA, Australia; San Francisco, CA; and Modena, Italy). 
Patients with IPF were followed for a minimum of 1 year and progression was defined as 
a significant decline in lung function or death. Primary parenchymal lung fibroblasts of 
15 patients with and without IPF were cultured under nonstimulatory conditions. Fibulin-1 
levels in serum, and secreted or deposited by fibroblasts, were measured by western blot 
and in lung tissue by immunohistochemistry. 
 RESULTS:  Serum fi bulin-1 levels were increased in patients with IPF compared with subjects 
without lung disease ( P  5 .006). Furthermore, tissue fi bulin-1 levels were increased in patients 
with IPF ( P  5 .02) and correlated negatively with lung function ( r  5  2 0.9,  P  , .05). Primary 
parenchymal fi broblasts from patients with IPF produced more fi bulin-1 than those from sub-
jects without IPF ( P  , .05). Finally, serum fi bulin-1 levels at fi rst blood draw predicted disease 
progression in IPF within 1 year (area under the curve , 0.71; 95% CI, 0.57-0.86;  P  5 .012). 
 CONCLUSIONS:  Fibulin-1 is a novel potential biomarker for disease progression in IPF and 
raises the possibility that it could be used as a target for the development of new treatments. 
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 ABBREVIATIONS: CPI  5 composite physiologic index; D lco  5 diff using 
capacity of the lung for carbon monoxide; ECM  5 extracellular matrix; 
ILD  5 interstitial lung disease; IPF  5 idiopathic pulmonary fibrosis; 
ROC  5 receiver-operator characteristic; TLC  5 total lung capacity 
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 Materials and Methods 
 Th is study contained three components. First we measured serum and 
lung tissue levels of fi bulin-1 in patients with IPF and from individuals 
without lung disease. Next, we used fi broblast cultures to assess fi bulin-1 
production. Finally, we explored the utility of serum fi bulin-1 as a bio-
marker of disease progression. 
 Study Approvals 
 Th is study was approved by the ethics committees of each of the six 
institutions involved in three countries; informed, written consent was 
obtained from all participants or their next of kin. Detailed ethics infor-
mation can be found in  e-Appendix 1 . 
 Fibulin-1 Levels in Serum 
 Serum was collected from three independent populations in Sydney, 
NSW, Australia; San Francisco, CA; and Modena, Italy, and included 
72 patients with IPF and 17 individuals without lung disease ( Table 1 ). 
A diagnosis of IPF was determined by multidisciplinary review as 
recommended by current guidelines. 16 Detailed characteristics of 
the three cohorts of patients with IPF are found in  e-Table 1 . Char-
acteristics of 79 additional patients with ILD are found in  e-Table 2 . 
Diagnoses included sarcoidosis (n  5 12), hypersensitivity pneumo-
nitis (n  5 32), and “other” ILDs defined as connective tissue disease-
related ILD (n  5 26), nonspecific interstitial pneumonia (n  5 4), 
lymphangioleiomyomatosis (n  5 4), and drug-induced ILD (n  5 1). 
Fibulin-1 levels were measured using densitometric analysis of western 
blots compared with a placental fi bulin-1 positive control. 
 Fibulin-1 Levels in Tissue 
 Lung parenchymal tissue was collected from four independent cohorts: 
Sydney, NSW, and Perth, WA, Australia; San Francisco, CA; and Modena, 
Italy. Lung function was measured within 30 days of tissue sampling. 
Characteristics of patients used for analysis of formalin-fi xed lung tissue 
are found in  Table 2 , while those for patients used for whole-lung lysate 
analysis were not available. Fibulin-1 levels were measured by quan-
tifi cation of immunohistochemical staining ( e-Fig 1 ) or western blot, 
respectively. Measurement of total collagen by quantifi cation of Masson 
 Idiopathic pulmonary fi brosis (IPF) is the most 
common of the idiopathic interstitial lung diseases 
(ILDs) and has the highest mortality. 1 Forty-four per-
cent of all patients with IPF are expected to die within 
5 years, compared with 33% of patients with ILD-
associated connective tissue disease and 2% of patients 
with pulmonary sarcoidosis, two other ILDs. 1 
 Treatments for IPF have been largely unsuccessful, 2,3 
mainly because the underlying mechanisms of IPF are 
unresolved and there is no biomarker available to pin-
point individuals with the risk of accelerated disease 
progression. Biomarkers in IPF refl ecting states of active 
fi brogenesis in the lung are needed to indicate those 
patients who will rapidly decline, so as to prioritize 
them for intensive management care and lung 
transplantation. 
 It is likely that common pathways driving fi brogenesis 
exist in many diseases with a fi brotic component. 4 Th e 
composition of the extracellular matrix (ECM) is an 
important and unifying factor in the pathophysiology 
of fi brosis, including lung fi brosis. 5 A number of ECM 
proteins also circulate in the blood. However, the utility 
of bloodborne ECM proteins as serum biomarkers in 
IPF has not been well investigated. 6,7 Th is refl ects our 
lack of knowledge as to which components of the ECM 
contribute particularly to the disease pathology of pul-
monary fi brogenesis and progression of the disease. 
 Th e glycoprotein fi bulin-1, which is found in both the 
ECM and the blood, is necessary for embryonic morpho-
genesis 8 and is essential for alveolar septa formation. 9 It is 
widely accepted in the literature that there are similarities 
between the development of fi brosis and embryonic mor-
phogenesis, 10 concepts not limited to the lung. 11 
 Fibulin-1 is produced by lung fi broblasts 12 and has been 
shown to play a role in the pathophysiology of patients 
with asthma, 13 a disease characterized in part by airway 
fi brosis. 14 We reasoned that dysregulated fi bulin-1 expres-
sion may be involved in lung diseases with more exten-
sive fi brosis as mechanisms of fi brogenesis are likely to 
be shared. 15 
 Th is study explored the role of fi bulin-1 in disease path-
ogenesis and progression of IPF. To this aim, we exam-
ined serum and tissue fi bulin-1 levels in patients with 
IPF and related it to lung function. We measured 
fibulin-1 production by lung fi broblasts derived from 
patients with IPF and from subjects without lung fi bro-
sis. Lastly, we investigated whether serum fi bulin-1 
could serve as a biomarker and assessed its prognostic 
utility in several cohorts of patients with IPF. 
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 TABLE 1 ]  Characteristics of Patients With IPF Used for Serum Analysis 
Characteristics All IPF (N  5 72) Stable (n  5 21) Progressed (n  5 27)  P Value
Mean (SD)
 Age, y 68 (9) 65 (11) 70 (9) ns a 
 FEV 1 , % predicted 79 (20) 79 (19) 76 (20) ns a 
 FVC, % predicted 74 (20) 78 (18) 68 (21) ns a 
 D LCO , % predicted 41 (16) 48 (18) 33 (14) .012 a 
 CPI, units 52 (13) 44 (14) 58 (10) .002 a 
 TLC, % predicted 67 (13) 75 (12) 63 (12) .027 a 
 Serum ﬁ bulin-1, units 2.04 (1.05) 1.59 (0.83) 2.34 (1.18) .013 a 
No. (%)
 Male sex 41 (57) 10 (48) 15 (56) ns b 
 History of smoking 45 (63) 14 (74) 19 (70) ns b 
 There were a total of 72 patients with IPF and of those 48 had follow-up information available. Continuous data of patients with IPF that either 
remained stable or progressed in the year following blood draw were compared by the Kruskal-Wallis test, and categorical data were compared with 
the Pearson  x 2 test. CPI  5 composite physiologic index; D LCO  5 diﬀ using capacity of the lung for carbon monoxide; IPF  5 idiopathic pulmonary ﬁ brosis; 
ns  5 nonsigniﬁ cant; TLC  5 total lung capacity. 
 a  P value for Kruskal-Wallis test. 
 b  P value for Pearson  x 2 test. 
trichrome staining was used as a positive control for fi brosis in tissue 
sections. 
 Fibulin-1 Levels in Parenchymal Fibroblasts 
 Human distal parenchymal fi broblasts were isolated from lung tissue 
obtained from patients with IPF (n  5 8) or pathologist-identifi ed mac-
roscopically nondiseased tissue from age-matched and sex-matched 
donors (n  5 7) undergoing resection for either thoracotomy or trans-
plantation. Demographic information for people from whom fi broblasts 
were derived is found in  e-Table 3 . Lung function measurements and 
smoking history were not available. Fibulin-1 levels were measured by 
western blot. 
 Serum Fibulin-1 as a Biomarker of Disease Progression 
 Patients with IPF were followed up for a minimum of 1 year (365   1 day) 
aft er blood draw. A progression event was defi ned as any of the follow-
ing occurring within the fi rst 1-year follow-up period:   10% relative 
fall in % predicted FVC,   15% relative fall in % predicted diff using 
capacity of the lung for carbon monoxide (D lco ), or death, as previ-
ously published. 17 
 Statistics 
 Statistical analysis was performed using SPSS (Version 21) (IBM). 
The coefficient of repeatability and intraclass correlation coefficient 
were calculated. 18 Distributions of serum, parenchyma, and fi broblast 
levels of fi bulin-1, and lung function parameters were tested for nor-
mality. Receiver-operator characteristic (ROC) curves were used to 
model the utility of serum fi bulin-1 as a marker of disease progres-
sion. Cox regression analysis was used to model the impact of serum 
fi bulin-1 levels on predicting progression. Kaplan-Meier curves were 
used to model time-to-progression event. Correlations between fi bulin-1 
and lung function parameters in patients with IPF were performed 
using Pearson product-moment tests. Between-group diff erences were 
assessed by unpaired  t , Kruskal-Wallis, Fisher exact,  x 2 , and log-rank 
tests, or analysis of covariance where appropriate. A  P value   .05 was 
considered signifi cant. Additional methods can be found in  e-Appendix 1 . 
 Results 
 Serum Fibulin-1 Levels Are Increased in Patients 
With IPF 
 Serum fibulin-1 levels were significantly higher in 
patients with IPF compared with subjects without lung 
disease aft er adjustments for potential confounding var-
iables: age, sex, and smoking history ( Fig 1 ,  e-Table 4 ). 
Th e serum fi bulin-1 levels were comparable in the three 
independent populations of patients with IPF ( e-Table 1 ). 
Serum fi bulin-1 levels were also increased in patients 
with IPF compared with patients with sarcoidosis, 
and patients with other ILDs, but there was no diff erence 
compared with patients with hypersensitivity pneumo-
nitis ( e-Fig 2 ,  e-Table 4 ). Serum fibulin-1 levels did 
not correlate with lung function variables in patients 
with only IPF ( e-Table 5 ) but did correlate with lung 
function when all ILDs were included in the analysis 
( e-Fig 3 ,  e-Table 6 ). 
 Tissue Fibulin-1 Levels Are Higher 
in Patients With IPF 
 Th e level of fi bulin-1 in whole-lung lysates from patients 
with IPF (mean, 3.43 units; SD, 0.91) was 2.6-fold 
higher than in subjects without lung disease (mean, 
1.34; SD, 0.2;  P  5 .02) ( Fig 2A ). Representative images 
of fi bulin-1 and Masson trichrome-stained tissue from 
patients with IPF and subjects without lung disease are 
shown in  Figure 2B . Th e level of fi bulin-1 in formalin-fi xed 
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tissue sections was signifi cantly higher in patients with 
IPF (mean, 129.2 units; SD, 4.32) compared with sub-
jects without lung disease (mean, 118.6; SD, 3.73; 
 P  , .001) ( Fig 2C ). Th ere was no signifi cant diff erence 
in fi bulin-1 levels in explanted lung tissue ( P  5 .24) 
( Fig 2C ). More collagen (percentage area stained with 
Masson trichrome) was measured in tissue from 
patients with IPF (n  5 12; mean, 25.0% area; SD, 10.5) 
than in tissue from subjects without lung disease (n  5 5; 
mean, 12.1; SD, 6.4;  P  5 .02) ( Fig 2D ). 
 Tissue Fibulin-1 Correlates With Lung Function in 
Patients With IPF 
 Higher tissue fi bulin-1 levels correlated signifi cantly 
with lower % predicted FEV 1 and FVC measurements 
(FEV 1 :  r  5  2 0.86,  P  5 .014; FVC:  r  5  2 0.92,  P  5 .004) 
( Fig 3 ). Tissue fibulin-1 levels did not significantly 
correlate with age, D lco , composite physiologic index 
(CPI), or % predicted total lung capacity (TLC) (data 
not shown). 
 Fibroblasts From Patients With IPF Produce 
More Fibulin-1 
 To investigate a potential source of the increase in fi bulin-1, 
we compared the secreted and cell-associated levels of 
fi bulin-1 in primary parenchymal fi broblasts from 
patients with IPF with age-matched and sex-matched 
subjects without lung disease under nonstimulated cell-
culture conditions in fi broblasts at low passage number 
(at most fi ve passages). Fibroblasts derived from patients 
with IPF produced signifi cantly more secreted fi bulin-1 
than fi broblasts from subjects without IPF ( P  5 .003) 
( Fig 4A ). Fibroblasts from patients with IPF produced 
more cell-associated fi bulin-1 than fi broblasts derived 
from subjects without IPF ( P  5 .007) ( Fig 4B ). 
 Serum Fibulin-1 Predicts Progression in IPF 
 Of the 72 patients with IPF, 48 patients were available 
for 1-year follow-up. In the year following blood draw, 
27 patients had a progression event and 21 patients 
remained stable. Patients who later progressed had 
poorer D lco , CPI, and TLC at the time of blood draw 
than those who did not progress ( Table 1 ). Th ere was no 
diff erence in FEV 1 , FVC, age, sex, or history of smoking 
between the two groups. 
 Serum fi bulin-1 levels were 1.5 times higher in patients 
with IPF who experienced a progression event (mean 
2.34 units, SD 1.18) compared with patients who 
remained stable (mean 1.59 units, SD 0.83;  P  5 .013) 
( Table 1 ). Th e area under the ROC curve was 0.71 
(95% CI, 0.57-0.86;  P  5 .012) ( Fig 5A ). From this curve, 
thresholds for fi bulin-1 levels were generated and sensi-
tivity and specifi city at each fi bulin-1 level were esti-
mated. Th ree thresholds (1.1, 1.6, and 2.9) were chosen 
for their diff ering specifi city and sensitivity profi les and 
 Figure 1 – Serum fi bulin-1 levels are increased in patients with IPF com-
pared with nondiseased subjects. Serum fi bulin-1 levels in patients with 
IPF, measured by western blot analysis of equal volumes of serum, were 
normalized against a standard serum sample loaded onto every gel. 
Densitometric values were transformed to natural log values before 
analysis. Data were adjusted for age, sex, and smoking history. Analysis 
of covariance, Sydney cohort n  5 27; , San Francisco cohort, n  5 17; , 
Modena cohort, n  5 28; , posttest Tukey; ***P  5 .006, median   25th 
and 75th percentiles. IPF  5 idiopathic pulmonary fi brosis. 
 TABLE 2 ]  Characteristics of Patients Used for Lung 
Tissue Analysis 
Characteristics
Nondiseased 
Control (n  5 5) IPF (n  5 20)  P Value
Mean (SD)
 Age, y 38 (14) 59 (8) .03 a 
 FEV 1 , % predicted n/a 77 (21) n/a a 
 FVC, % predicted n/a 74 (20) n/a a 
 D LCO , % predicted n/a 42 (20) n/a a 
 CPI, units n/a 52 (16) n/a a 
 TLC, % predicted n/a 81 (18) n/a a 
Count (%)    
 Male 4 (80) 14 (70) .24 b 
 Continuous data were compared by unpaired  t tests, and categorical 
data by Fisher exact test. n/a  5 not applicable. See  Table 1 legend for 
expansion of other abbreviations. 
 a  P value for unpaired  t test. 
 b P value for Fisher exact test. 
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 Figure 2 – Tissue fi bulin-1 and collagen levels in lung parenchyma from IPF and nondiseased subjects. A, Levels of fi bulin-1 in lysates of parenchyma 
from patients with IPF (n  5 4) and nondiseased subjects (n  5 4) were analyzed by western blot and densitometric values were normalized to GAPDH 
detected on the same blots. A representative blot is shown. Lane 1, Cell lysate from fi bulin-1 transfected HT1080 fi brosarcoma cells. Total protein (1.5  m g) 
of whole-lung lysates from nondiseased subjects (lanes 2-5) and patients with IPF (lanes 6-9) were loaded. B, Th e normalized densitometric values were 
compared by unpaired  t test; *P  , .05. C-F, Immunostaining of fi bulin-1, detected using a chemical chromophore DAB (brown) and Masson trichrome 
staining for detection of collagen (green) in formalin-fi xed tissue sections from patients with IPF and nondiseased subjects was analyzed by computer-
ized image analysis. Twenty images were taken at random from two to six sections per patient (fi bulin-1 IPF: n  5 5 explanted lungs, n  5 15 surgical 
biopsies, nondiseased subjects n  5 5; collagen IPF: n  5 12 surgical biopsies, nondiseased subjects n  5 5). Representative images in nondiseased subjects 
(C, fi bulin-1; D, collagen) and patients with IPF (E, fi bulin-1; F, collagen). In images, black triangle indicates airway, black solid arrow indicates blood 
vessel, black dashed arrow indicates alveolar septa. Fibulin-1 staining is distributed throughout the lung parenchyma but may be more concentrated in 
cells within the alveolar space (black lightning bolt). G-H, Averaged staining levels for (G) fi bulin-1 and (H) collagen were compared using analysis of 
variance (**P  5 .005, fi bulin-1) and unpaired  t test (*P  , .05, collagen). Values are expressed in all graphs as mean   SD. Magnifi cation,  3 20; black 
scale bar, 200  m m. DAB  5 diaminobenzidine; GAPDH  5 glyceraldehyde 3-phosphate dehydrogenase. See  Figure 1 legend for expansion of other 
abbreviation. 
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subjected to further analysis. At a threshold of 1.6 units, 
serum fi bulin-1 identifi ed patients with IPF who pro-
gressed with 70% sensitivity and 71% specifi city. At 
thresholds of 1.1 and 2.9 units, the sensitivities and 
specifi cities were 93% and 33%, and 30% and 90%, respec-
tively ( e-Table 7 ). Kaplan-Meier curves showed that 
patients with IPF with a serum fi bulin-1 level  . 1.6 units 
had a shorter progression-free survival time than those 
with   1.6 units ( P  5 .003) ( Fig 5B ,  Table 3 ). The 
progression-free survival rates of patients with IPF with 
high or low serum fi bulin-1 levels were also signifi cantly 
diff erent if thresholds of 1.1 units or 2.9 units were used 
to stratify the groups (1.1 units,  P  5 .016; 2.9 units,  P  5 .019) 
( Table 3 ). An increase in 1 unit of serum fibulin-1 
level in patients with IPF carried a significant hazard 
ratio for the likelihood of disease progression of 1.69 
(95% CI, 1.2-2.3;  P  5 .001). 
 Univariate logistic regression showed that age, history 
of smoking, or FVC did not predict disease progression 
in our study population. When the variables serum 
fi bulin-1, age, history of smoking, FVC, and D lco were 
analyzed simultaneously in the multivariate model, the 
independent contribution of serum fi bulin-1 increased 
to 2.11 (95% CI, 1.3-3.5;  P  5 .004) ( e-Table 8 ). D lco did 
not predict disease progression in the multivariate model. 
 A patient with IPF with a level of serum fi bulin-1  . 1.6 units 
was five times more likely to progress compared with 
a patient with a level of serum fibulin-1   1.6 units 
(hazard ratio, 5.2; 95% CI, 2.0-13.3;  P  5 .001). 
 Discussion 
 To our knowledge, this is the fi rst study reporting the 
signifi cance of fi bulin-1 in the severity and disease pro-
gression of IPF. Th e increased levels of fi bulin-1 found 
in the serum, lung tissue, and primary fi broblast cul-
tures of patients with IPF indicate fi bulin-1 may con-
tribute to this disease and importantly, a high serum 
fi bulin-1 level may serve as a biomarker for disease pro-
gression. Moreover, the fi ndings of this study were 
derived from four separate patient cohorts from three 
diff erent countries, which is important, as IPF is a vari-
able and global disease. 
 We have previously observed raised fi bulin-1 levels in 
the serum and BAL fl uid of patients with asthma, 13 a 
 Figure 3 – Lung tissue fi bulin-1 levels in patients with IPF inversely 
correlate with lung function measurements. A-B, Averaged tissue fi bu-
lin-1 levels for each patient with IPF (n  5 7) were compared with their 
(A) FEV 1 and (B) FVC measurements. Each solid circle represents the 
average lung tissue fi bulin-1 level of two to six individual biopsies per 
patient. Pearson product-moment coeffi  cients: FEV 1 :  r  5  2 0.86, 
P  5 .014; FVC:  r  5 0.92,  P  5 .004. See Figure 1 legend for expansion of 
abbreviation. 
 Figure 4 – Parenchymal fi broblasts from patients with IPF produce more fi bulin-1 than fi broblasts from patients without respiratory disease. Primary 
parenchymal fi broblasts from patients with IPF (n  5 8) and age-matched and sex-matched patients without respiratory disease (n  5 7) were grown for 
72 h in 5% fetal bovine serum (FBS), quiesced in 0.1% FBS for 24 h and maintained in fresh 0.1% FBS for a further 72 h. Supernatants and cell lysates 
were collected and analyzed by western blot. A-B, Densitometric values were normalized to total protein (supernatants, A) or GAPDH detected on the 
same blots (cell lysates, B). Unpaired  t test. **P  , .01. Values are expressed as median and interquartile range. See  Figure 1 and 2 legends for expansion 
of abbreviations. 
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disease in which fi brosis of the airways is associated 
with disease progression. 14 Across diseases in which 
fi brosis occurs there are similar mechanisms contributing 
to fi brogenesis. 15 Hence, it was logical to explore 
whether fi bulin-1 would also be important in a disease 
predominantly characterized by fi brosis, that is, IPF. 
Alterations in fi bulin-1 levels have been observed in a 
number of diseases. Plasma levels of fi bulin-1 were iden-
tifi ed as a potential marker for kidney malfunction, 19 
and increased levels of fi bulin-1 were detected in sera 
from patients with preeclampsia. 20 It is likely that the 
feature common to these diseases and the lung disease 
we studied is active fi brosis. 
 If fi bulin-1 were to be biologically important during 
active fi brosis, then levels of fi bulin-1 would likely be 
related to measurements of disease severity. While 
much of the focus in the literature has centered on the 
importance of collagen to fi brosis, 21 it is possible that 
smaller ECM-connecting proteins, 22 like fi bulin-1 which 
binds to elastic fi bers, 12 can also act to alter the mechan-
ical properties of the lung. 23 In this study, as the levels 
of tissue fi bulin-1 increased, the lung function of the 
patients decreased. Given that fi bulin-1 is a known 
modulator of the ECM during the progression of some 
diseases, 24 this fi nding is indicative of the potential 
importance of fi bulin-1 as a target during fi brogenesis. 
 Figure 5 – Serum fi bulin-1 levels predict disease progression in patients with IPF. Patients with IPF were followed up for at least 1 year (365   1 d) 
following blood draw. A, Fibulin-1 levels in patients who progressed (n  5 27) were compared with the levels in patients who did not progress (n  5 21) 
and a receiver operating characteristic (ROC) curve was generated. Th e area under the curve was 0.71 (95% CI, 0.57-0.86; P  5 .012). B, Kaplan-Meier 
survival curves showing time to progression event were generated. Patients who had a serum fi bulin-1 of   1.6 units (n  5 23, dashed line) were com-
pared with patients who had a level of  . 1.6 units (n  5 25, solid line). Circles on each line represent time censoring. Mantel-Cox log rank, **P  5 .003. 
See Figure 1 legend for expansion of abbreviation. 
 TABLE 3 ]  Progression-Free Survival Time Comparison in Patients With IPF 
Threshold and Fibulin-1 Level Total No. No. of Progressed
Average Time to Progression Event (d)
Estimate SE
95% CI
 P ValueLower Upper
1.1 units .016
 Low 10 2 1,772 360 1,066 2,478
 High 38 25 704 167 377 1,031
1.6 units .003
 Low 23 8 1,509 241 1,036 1,982
 High 25 19 433 156 128 738
2.9 units .019
 Low 39 20 1,056 197 670 1,441
 High 9 7 215 35 146 283
 Patients with IPF who presented with a high level of serum ﬁ bulin-1 had a shorter progression-free survival time compared with those who had a low 
level of serum ﬁ bulin-1. The progression-free survival time of patients who presented with a high level of ﬁ bulin-1 (greater than the threshold of 1.1, 
1.6 or 2.9) and low level of ﬁ bulin-1 (less than or equal to the threshold of 1.1, 1.6 or 2.9) were compared using the Mantel-Cox log-rank test. See 
 Table 1 legend for expansion of abbreviation. 
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 Primary parenchymal fi broblasts derived from patients 
with IPF produced more secreted and cell-associated 
fi bulin-1 than fi broblasts derived from patients without 
IPF. Th e contribution of particular ECM molecules to 
the development of fi brogenesis has not been extensively 
investigated in IPF, as research has largely focused on 
either chemokines or circulating progenitors of myofi bro-
blasts as targets to dampen the “profi brotic environ-
ment” that drives fi brosis. 25 Furthermore, there is evidence 
that the stiff ness of the underlying matrix alters fi bro-
blast behavior. 26 It is possible that excessive production 
of secreted fi bulin-1 by the resident fi broblasts of 
patients with IPF contributes to the increased fi bulin-1 
level found in the blood. In addition, the increased 
production of fi bulin-1 likely refl ects in the activated 
fibrogenic state of fibroblasts derived from patients 
with IPF. 
 A number of serum biomarkers of disease severity and 
progression in IPF have been identifi ed and reviewed. 6,7 
Th ese include the MUC5B gene polymorphism, 27 
mucin-1 (KL-6), surfactant proteins SP-A and SP-D, 
matrix metalloproteinases 1 and 7, chemokines CCL18 
and CXCL8, calgranulin B (S100A12), intracellular 
adhesion molecule 1 (ICAM-1) and vascular cell adhesion 
protein 1 (VCAM-1), and periostin. 28 While it is likely 
that numerous factors will contribute to the develop-
ment of fi brosis, the strength of our focus on fi bulin-1 
is the consistent fi nding in multiple patient cohorts and 
the multiple forms, soluble and tissue incorporated, of 
the protein that were increased. In addition, lung 
tissue fibulin-1 levels relate to physiologic measure-
ments of lung function in patients with IPF. 
 An important finding from this study for the future 
management of IPF is the observation that serum 
fi bulin-1 levels have predictive value for acute disease 
progression in patients with IPF. There was a 71% 
chance that there was a higher serum fibulin-1 level 
in a patient with IPF who progressed within 1 year 
compared with a patient who remained stable. In 
addition, patients with a high level of serum fibulin-1 
had a higher likelihood of progression and a shorter 
progression-free survival time compared with their 
low fibulin-1 counterparts. Serum levels were highest 
in patients with IPF compared with patients with other 
ILDs but correlated with lung function variables in all 
patients with ILD, suggesting that serum fi bulin-1 
levels may predict disease progression in other fibrosing 
ILDs, such as idiopathic nonspecific pneumonia. 
 It is crucial to identify factors able to categorize which 
patients with IPF will rapidly decline compared with 
those patients with a more stable form of the disease. 
Further follow-up studies in a larger sample size are 
needed to confi rm the potential use of fi bulin-1 levels 
for the stratifi cation of patients with IPF. Th is informa-
tion will enable clinicians to optimize early referral to 
transplantation programs and palliative care. Fibulin-1 
may be a useful tool to stratify patients for inclusion in 
future therapeutic trials and to guide future manage-
ment decisions. 
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